Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10145	Sitravatinib
BP10145	Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
BP10352	SKF-96365 hydrochloride
BP10352	SKF-96365, a SOCE inhibitor, exhibits potent anti-neoplastic activity by inducing cell-cycle arrest and apoptosis in colorectal Y cells. SKF-96365 can induce cytoprotective autophagy to delay apoptosis by preventing the release of cytochrome c (cyt c) from the mitochondria into the cytoplasm. Mechanistically, SKF-96365 treatment inhibited the calcium/calmodulin-dependent protein kinase IIγ (CaMKIIγ)/AKT signaling cascade in vitro and in vivo. Overexpression of CaMKIIγ or AKT abolished the effects of SKF-96365 on Y cells, suggesting a critical role of the CaMKIIγ/AKT signaling pathway in SFK-96365-induced biological effects. SKF-96365 inhibited hERG current in a concentration-dependent manner.
BP10313	SKI-178
BP10313	SKI-178 is a sphingosine kinase 1 (SphK1) inhibitor with IC50 of 0.1-1.8 μM. It induces prolonged mitosis followed by apoptotic cell death through the intrinsic apoptotic cascade. The sustained activation of CDK1 during prolonged mitosis, mediated by SKI-178 leads to the simultaneous phosphorylation of the prosurvival Bcl-2 family members, Bcl-2 and Bcl-xl, as well as the phosphorylation and subsequent degradation of Mcl-1.
BP10154	SKLB 610
BP10154	SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, at the concentration of 10 μM in biochemical kinase assays.
BP10256	SKLB1002
BP10256	SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.
BP10297	SKLB-163
BP10297	SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
BP10431	SKLB4771
BP10431	FLT3-IN-1 is a novel potent and selective Flt3 inhibitor.
BP10532	SMIP004
BP10532	SMIP004 is an SKP2 E3 ligase inhibitor. SMIP004 is a cancer cell-selective apoptosis inducer of human prostate cancer cells.
BP10756	Sodium 4-phenylbutyrate
BP10756	Sodium Phenylbutyrate, a transcriptional regulator, reversibly inhibits class I and II histone deacetylases (HDACs )resulting in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.
BP10981	Sodium Aescinate
BP10981	Sodium Aescinate is extracted from Aesculus wilsonii.
BP10318	Purapuridine
BP10318	Purapuridine (Solasodine) is a poisonous alkaloid chemical compound that occurs in plants of the Solanaceae family. Solasodine showed selective cytotoxicity against cervical cancer cell line (HeLa) and human myeloid leukemia cell line (U937).
BP10231	Solcitinib
BP10231	Solcitinib (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus.
BP10563	Sophocarpine monohydrate
BP10563	Sophocarpine, a major ingredient of Sophora alopecuroides, has a wide range of pharmacological effects.
BP10157	Sorafenib-d3
BP10157	Sorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
BP10293	SP-141
BP10293	SP 141 is a MDM2 inhibitor.SP-141 promotes MDM2 auto-ubiquitination and degradation, with anticancer activity.
BP10507	SP2509
BP10507	SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).
BP10346	SP600125
BP10346	SP600125 is a JNK1/2/3 inhibitor (IC50: 40/40/90 nM) and 10-fold higher selectivity than MKK4, 25-fold higher selectivity than MKK3, MKK6, PKCα, and PKB.
BP10321	Spautin-1
BP10321	Spautin-1 is a novel autophagy inhibitor, IM inhibited the growth of K562 cells with IC50 of 1.03 μM. In contrast, co-treatment with Spautin-1 increased IM-induced inhibition of cell viability with IC50 of 0.45 μM.
BP10081	SPD304 dihydrochloride
BP10081	SPD304 dihydrochloride is a selective inhibitor of TNF-α with an IC50 of 22 µM. SPD304 dihydrochloride promotes dissociation of TNF trimers.
BP10226	Spebrutinib
BP10226	Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.